Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Lag Attributable to Delay in Starting Clinical Trials: OPIR Study
October 13, 2008
- REGULATORY NEWS IN BRIEF
October 13, 2008
- NEW PRODUCTS
October 13, 2008
- Original and Generic Amlodipine Products Show Same Effects
October 13, 2008
- Kyowa Hakko Kirin Sets Out Aiming at Becoming Global Specialty Pharma
October 13, 2008
- GENERICS NEWS IN BRIEF
October 13, 2008
- Argatroban to Be Temporarily Excluded from DPC Payment
October 6, 2008
- Levemir Reduces Risk of Nocturnal Hypoglycemia: Novo Nordisk
October 6, 2008
- Tamiflu Ban in Teenagers Should Not Be Lifted: Medwatcher Japan
October 6, 2008
- H. Pylori Eradication Should Be Covered by Health Insurance
October 6, 2008
- Chuikyo to Continue Discussions on NHI Pricing System Reform Proposed by Industry
October 6, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 6, 2008
- FPMAJ Explains Its NHI Pricing System Reform Proposal
October 6, 2008
- Teva Ties Up with Kowa to Fully Enter Japanese Market for Generics
October 6, 2008
- New Prime Minister Taro Aso Reappoints Yoichi Masuzoe as Health Minister
October 6, 2008
- JT Licenses Oral Drug for Osteoporosis to Merck of the US
October 6, 2008
- Takeda Applies for Alogliptin/ACTOS Combination in the US
October 6, 2008
- All of the Top Five Drugs Were ARBs in August: Rep Track Survey
October 6, 2008
- REGULATORY NEWS IN BRIEF
October 6, 2008
- Alfresa HD Ties Up with Medical System Network
October 6, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…